A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

Also called NCT02280083

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 180 participants (enrolled count) (from the registry)
Sponsor
Lanzhou Institute of Biological Products Co., Ltd (from the registry)
Registry
  • NCT NCT02280083
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02280083. Randomized; quadruple masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2016-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity
Condition
Cerebrovascular Accident
Intervention (Drug)
Botulinum Toxin Type A for Injection
Intervention (Drug)
placebo
Lead sponsor
Lanzhou Institute of Biological Products Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct02280083
Content hash
1b142bf7efe5ae006c5f5e78b1c51ac1ae485ddd30e0fa53a5ed147185be2afb